The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
April 19th 2024
Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases
Hepatitis Awareness Month: Help Your Patients Live(r) Longer
Many of patients with hepatitis that pharmacists encounter have viral hepatitis, which can be easily remembered as the ABCs of hepatitis.
Read More
Hepatitis C Is Widespread but Rarely Treated in Postpartum Medicaid Beneficiaries With OUD
April 12th 2022Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.
Read More
New Research Finds Patient Out-of-Pocket Spending Increased for Hepatitis B Medication
February 4th 2022During that time period, patients with high-deductible health plans spent on average $133 per 30-day supply, a cost threshold associated with a more than 50% rate of prescription abandonment, according to the researchers.
Read More
How Pharmacists Can Help Address Health Disparities Among Asian Americans
May 18th 2021According to the US Department of Health and Human Services Office of Minority Health, Asian Americans are 40% more likely to be diagnosed with diabetes and 60% more likely to be diagnosed with renal disease compared to non-Hispanic whites.
Read More
New Findings Suggest Hepatitis C Drugs May Multiply Effect of COVID-19 Antiviral Remdesivir
May 3rd 2021The finding raises the potential for repurposing available drugs as COVID-19 antivirals for cases in which a vaccine is not practical or effective, according to RPI chemistry and chemical professor Gaetano Montelione.
Read More
More Than 100 Patient Groups Advocate for Affordable Prescription Drugs
April 27th 2021Patient and provider organizations urge the Department of Health and Human Services and the Biden administration to enact policies and protections that improve prescription drug affordability for people in the United States.
Read More